Aryl Hydrocarbon Receptor is a Target of 17-Allylamino-17-demethoxygeldanamycin and Enhances its Anticancer Activity in Lung Adenocarcinoma Cells

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor <i>EML4-ALK</i>

Alice T. Shaw, Beow Y. Yeap, Mari Mino–Kenudson et al. · Journal of Clinical Oncology · 2009 · 1.9K citations · Full text

Medicine, Genetics, Oncology +17

Crystal Structure of an Hsp90–Geldanamycin Complex: Targeting of a Protein Chaperone by an Antitumor Agent

C. Erec Stebbins, Alicia A. Russo, Christine Schneider et al. · Cell · 1997 · 1.4K citations · Full text

Life Sciences, Biochemistry, Oncology +17

Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?

Clinical Cancer Research · 2012 · 903 citations · Full text

Medicine, Oncology, Pharmacology +16

International lung cancer trends by histologic type: Male:Female differences diminishing and adenocarcinoma rates rising

Susan S. Devesa, Freddie Bray, A. Paloma Vizcaino et al. · International Journal of Cancer · 2005 · 750 citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK

Ryohei Katayama, Tahsin M. Khan, Cyril H. Benes et al. · Proceedings of the National Academy of Sciences · 2011 · 540 citations · Full text

Medicine, Oncology, Pharmacology +16